ArticleChemical record (New York, N.Y.)2025
Dicyanopyrazine: 10th Anniversary in Photoredox Catalysis.
Article in Chemical record (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dicyanopyrazine: 10th Anniversary in Photoredox Catalysis.Chemical record (New York, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The last decade unveiled dicyanopyrazine as a purely organic photocatalyst capable of initiating a variety of unprecedented photoredox transformations. The latest discoveries also pointed to a facile Mallory-type photocyclization of the catalyst to quinoxaline-2,3-dicarbonitrile derivative, which proved to be the active catalytic species. Its principal photochemical properties involve the absorption band covering the blue spectral region, a sufficiently long-lived triplet, and the reversible first reduction accompanied by the formation of the corresponding radical anion. Hence, two-photon photoredox catalysis via (consecutive) photoinduced electron transfer can be conveniently accomplished to either oxidize or reduce various substrates. This review summarizes the first synthetic attempts toward dicyanopyrazine catalyst, its further improvements, structural modifications, photochemical properties, and also covers the application of pyrazine-2, 3-dicarbonitirle and quinoxaline-2,3-dicarbonitrile-based photocatalysts across the photoredox catalysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.